Patient-led hypothesis links mast cell activation syndrome and histamine H₃ receptors to treatment-resistant ADHD and anxiety, suggesting new avenues for research.
This is a patient-led hypothesis paper proposing that mast cell activation syndrome (MCAS) and histamine H₃ receptor pathways may contribute to treatment-resistant attention-deficit/hyperactivity disorder (ADHD), anxiety, and post-COVID cognitive dysfunction. Drawing on personal observations and literature review, the author suggests that chronic histamine release via H₃ receptors could disrupt dopamine, norepinephrine, and acetylcholine signaling, contributing to neuroinflammation and impaired focus, mood, and cognition. This work is intended to stimulate discussion, research, and collaboration in both the clinical and scientific communities. It does not constitute clinical advice.
No takes yet. Share an insight, caveat, or question.
Andrii Zlotnikov (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: